What is Istalol and Optive used for?

Istalol and Optive is indicated for Glaucoma and ocular hypertension (Istalol), Dry eye syndrome (Optive).

Who makes Istalol and Optive?

Istalol and Optive is developed by Bp Consulting, Inc.

What development phase is Istalol and Optive in?

Istalol and Optive is FDA-approved (marketed).

What are the side effects of Istalol and Optive?

Common side effects include Ocular irritation or stinging (Istalol), Blurred vision (Istalol), Temporary blurred vision (Optive), Eye discomfort (Optive).

Last reviewed 2026-04-22 · How we verify

Istalol and Optive

Bp Consulting, Inc · FDA-approved active Small molecule

Istalol is a beta-blocker that reduces intraocular pressure by decreasing aqueous humor production, while Optive is a lubricating eye drop that provides ocular surface hydration and protection.

Istalol is a beta-blocker that reduces intraocular pressure by decreasing aqueous humor production, while Optive is a lubricating eye drop that provides ocular surface hydration and protection. Used for Glaucoma and ocular hypertension (Istalol), Dry eye syndrome (Optive).

At a glance

Generic name	Istalol and Optive
Sponsor	Bp Consulting, Inc
Drug class	Beta-blocker (Istalol); Artificial tear/lubricant (Optive)
Target	Beta-adrenergic receptors (Istalol); Non-specific ocular surface lubricant (Optive)
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	FDA-approved

Mechanism of action

Istalol (timolol) works as a non-selective beta-adrenergic antagonist that inhibits aqueous humor secretion in the eye, thereby lowering intraocular pressure in glaucoma and ocular hypertension. Optive is a combination artificial tear formulation containing carboxymethylcellulose and glycerin that lubricates and protects the ocular surface, commonly used for dry eye syndrome. These are distinct products with different mechanisms targeting different ocular conditions.

Approved indications

Glaucoma and ocular hypertension (Istalol)
Dry eye syndrome (Optive)

Common side effects

Ocular irritation or stinging (Istalol)
Blurred vision (Istalol)
Temporary blurred vision (Optive)
Eye discomfort (Optive)

Key clinical trials

Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Istalol and Optive CI brief — competitive landscape report
Istalol and Optive updates RSS · CI watch RSS
Bp Consulting, Inc portfolio CI